Advanced Care for Treatment‑Resistant Depression

At Castle Healthcare Services Inc., we provide FDA‑approved esketamine nasal spray (Spravato®) for patients struggling with treatment‑resistant depression, severe depressive symptoms, or suicidal ideation. Unlike traditional antidepressants, Spravato® works rapidly to relieve symptoms and is administered under the supervision of our licensed providers in a safe, supportive environment.

What Is Spravato®?

● Esketamine Nasal Spray — FDA‑approved in 2019 for adults with treatment‑resistant depression.
● Rapid Relief — Many patients experience improvement within 24 hours.
● Safe & Supervised — Administered in‑clinic with monitoring for comfort and safety.
● Insurance Coverage — Most major insurance plans cover Spravato® after two failed antidepressant trials.
Treatment Plan

Your personalized treatment plan is designed to maximize safety and effectiveness:

Phase 1: Induction (Weeks 1–4)
●2 treatments per week
●Each session lasts about 2 hours (including monitoring)
Phase 2: Maintenance (Weeks 5–8)
● 1 treatment per week
● Adjusted based on your provider’s recommendations
Phase 3: Ongoing Care
● Continued treatments as needed
● Integrated with therapy and medication management for long‑term stability

During Each Session:

● Self‑administered nasal spray under provider supervision
● Blood pressure monitored before, during, and after treatment
● Patients remain in clinic for 2 hours post‑administration
● Must arrange transportation home (no driving after treatment).